Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin (ENHANCE)
Phase 4 Study Using Infergen and Ribavirin in Patients With Chronic Hepatitis C Virus Who Achieved Partial Response to Peginterferon-alfa and Ribavirin Therapy
Sponsor: Kadmon Corporation, LLC
Terminated
slow enrollment
Other terminated trials from Kadmon Corporation, LLC
- Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Phase PHASE2 · Dec 2016
- HER-2 Positive Breast Cancer · Phase PHASE1/PHASE2 · Sep 2015
- Carcinoma, Non-Small-Cell Lung · Phase PHASE3 · Jul 2013
More terminations from Kadmon Corporation, LLC
Listed as NCT00456248, this PHASE4 trial focuses on Hepatitis C and remains terminated or withdrawn. Sponsored by Kadmon Corporation, LLC, it has been updated 7 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
May 2022 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — May 2022 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
Feb 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kadmon Corporation, LLC
For direct contact, visit the study record on ClinicalTrials.gov .